CHAMPIONS ONCOLOGY, INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3cb74e14-1858-4c0f-a264-b9084d077373/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $59.4M | 2025-05-01 – 2026-04-30 | evidence 0001628280-26-049834 |
| FY 2024 | $56.9M | 2024-05-01 – 2025-04-30 | evidence 0001628280-25-035765 |
| FY 2023 | $50.2M | 2023-05-01 – 2024-04-30 | evidence 0001628280-24-032321 |
| FY 2022 | $53.9M | 2022-05-01 – 2023-04-30 | evidence 0001628280-23-025464 |
| FY 2021 | $49.1M | 2021-05-01 – 2022-04-30 | evidence 0001628280-22-019309 |
| FY 2020 | $41.0M | 2020-05-01 – 2021-04-30 | evidence 0001628280-21-014464 |
| FY 2019 | $32.1M | 2019-05-01 – 2020-04-30 | evidence 0001628280-20-010734 |
| FY 2018 | $27.1M | 2018-05-01 – 2019-04-30 | evidence 0001628280-19-009139 |
| FY 2017 | $20.2M | 2017-05-01 – 2018-04-30 | evidence 0001628280-19-009139 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CHAMPIONS ONCOLOGY, INC. — all facts · Net Income · Operating Income